Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue
Total revenue	$ 699,022	$ 448,713	$ 2,348,601	$ 1,885,663
Operating expenses
Cost of products sold	618,796	1,886,191	1,925,566	2,824,577
Cost of services	73,174	17,239	405,582	63,450
Research and development	1,201,865	2,031,113	4,403,488	6,621,310
General and administrative	2,034,628	2,020,452	6,883,588	6,779,773
Sales and marketing	336,184	1,031,496	2,522,471	3,252,277
Goodwill impairment charge		6,975,520		6,975,520
Total operating expenses	4,264,647	13,962,011	16,140,695	26,516,907
Operating loss	(3,565,625)	(13,513,298)	(13,792,094)	(24,631,244)
Other (expense) income
Interest and other income	24,977	11,174	86,301	28,147
Interest expense	(396,768)	(569,306)	(1,698,564)	(2,618,799)
Foreign currency transaction (losses) gains	(135,930)	(51,547)	(288,326)	419,160
Change in fair value of derivative financial instruments	10,389	18,995	65,800	54,623
Total other expense	(497,332)	(590,684)	(1,834,789)	(2,116,869)
Loss before income taxes	(4,062,957)	(14,103,982)	(15,626,883)	(26,748,113)
Provision for income taxes
Net loss	(4,062,957)	(14,103,982)	(15,626,883)	(26,748,113)
Net loss available to common stockholders	$ (4,062,957)	$ (14,103,982)	$ (15,626,883)	$ (26,748,113)
Net loss per common share – basic (in Dollars per share)	$ (0.46)	$ (5.92)	$ (2.38)	$ (11.4)
Weighted average shares outstanding – basic (in Shares)	8,778,152	2,382,848	6,565,853	2,345,794
Net loss	$ (4,062,957)	$ (14,103,982)	$ (15,626,883)	$ (26,748,113)
Other comprehensive income (loss) – foreign currency translation	78,815	(536,758)	118,178	(2,247,749)
Comprehensive loss	(3,984,142)	(14,640,740)	(15,508,705)	(28,995,862)
Product sales
Revenue
Total revenue	558,965	359,112	1,409,534	1,614,435
Laboratory services
Revenue
Total revenue	47,135	31,016	112,810	94,515
Collaboration revenue
Revenue
Total revenue	$ 92,922	$ 58,585	$ 826,257	$ 176,713